The DOI matches its Crossref record; 83 of the 83 references it cites were found in a registry or an index.
N-glycosylation heterogeneity and the influence on structure, function and pharmacokinetics of monoclonal antibodies and Fc fusion proteins
Open accessAbstract
Monoclonal antibody and Fc fusion protein drugs are complex heterogeneous mixtures of numerous different protein variants and modifications. N-glycosylation as one of the most complex post-translational modification influences the structural characteristics of the antibodies Fc part thereby potentially modulating effector function and pharmacokinetics. Several investigations on the relationship between N-glycosylation and pharmacokinetics have been published. However, this structure-function relationship is not fully understood. In this review potential alterations with focus on N-glycosylation of mAbs and Fc fusion proteins and the possible effects on the pharmacokinetics are reviewed and the current understandings of the underlying mechanisms are described.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Continuous cultures of fused cells secreting antibody of predefined specificity
KÖHLER, G., & MILSTEIN, C. (1975) · Nature · doi:10.1038/256495a0 · Cited by 17,229
FcRn: the neonatal Fc receptor comes of age
Roopenian, D. C., & Akilesh, S. (2007) · Nature Reviews Immunology · doi:10.1038/nri2155 · Cited by 2,346
Carbohydrate-Specific Receptors of the Liver
Ashwell, G., & Harford, J. (1982) · Annual Review of Biochemistry · doi:10.1146/annurev.bi.51.070182.002531 · Cited by 1,914
Shinkawa, T., Nakamura, K., Yamane, N., Shoji-Hosaka, E., Kanda, Y., Sakurada, M., Uchida, K., Anazawa, H., Satoh, M., Yamasaki, M., et al. (2003) · Journal of Biological Chemistry · doi:10.1074/jbc.m210665200 · Cited by 1,413
The role of sialic acid in determining the survival of glycoproteins in the circulation
Morell, A. G., Gregoriadis, G., Scheinberg, I. H., Hickman, J., & Ashwell, G. (1971) · Journal of Biological Chemistry · doi:10.1016/s0021-9258(19)76994-4 · Cited by 1,072
Mössner, E., Brünker, P., Moser, S., Püntener, U., Schmidt, C., Herter, S., Grau, R., Gerdes, C., Nopora, A., van Puijenbroek, E., et al. (2010) · Blood · doi:10.1182/blood-2009-06-225979 · Cited by 981
Antibody Structure, Instability, and Formulation
Wang, W., Singh, S., Zeng, D. L., King, K., & Nema, S. (2007) · Journal of Pharmaceutical Sciences · doi:10.1002/jps.20727 · Cited by 941
Antibody Pharmacokinetics and Pharmacodynamics
Lobo, E. D., Hansen, R. J., & Balthasar, J. P. (2004) · Journal of Pharmaceutical Sciences · doi:10.1002/jps.20178 · Cited by 909
Glycosylation as a strategy to improve antibody-based therapeutics
Jefferis, R. (2009) · Nature Reviews Drug Discovery · doi:10.1038/nrd2804 · Cited by 829 · cited 2×
“The glycan structures of therapeutic mAbs can be of importance for the efficacy and safety of the drug [21].”
BackgroundThe mechanism of human nonhomologous DNA end joining
Lieber, M. R. (2008) · Journal of Biological Chemistry · doi:10.1074/jbc.r700039200 · Cited by 720
Krapp, S., Mimura, Y., Jefferis, R., Huber, R., & Sondermann, P. (2003) · Journal of Molecular Biology · doi:10.1016/s0022-2836(02)01250-0 · Cited by 674
Yamane‐Ohnuki, N., Kinoshita, S., Inoue‐Urakubo, M., Kusunoki, M., Iida, S., Nakano, R., Wakitani, M., Niwa, R., Sakurada, M., Uchida, K., et al. (2004) · Biotechnology and Bioengineering · doi:10.1002/bit.20151 · Cited by 572
Terminal sugars of Fc glycans influence antibody effector functions of IgGs
Raju, T. S. (2008) · Current Opinion in Immunology · doi:10.1016/j.coi.2008.06.007 · Cited by 521
The asialoglycoprotein receptor: relationships between structure, function, and expression
Stockert, R. J. (1995) · Physiological Reviews · doi:10.1152/physrev.1995.75.3.591 · Cited by 520
Identification of multiple sources of charge heterogeneity in a recombinant antibody
Harris, R. J., Kabakoff, B., Macchi, F. D., Shen, F. J., Kwong, M., Andya, J. D., Shire, S. J., Bjork, N., Totpal, K., & Chen, A. B. (2001) · Journal of Chromatography B: Biomedical Sciences and Applications · doi:10.1016/s0378-4347(00)00548-x · Cited by 500
Liu, H., & May, K. (2012) · mAbs · doi:10.4161/mabs.4.1.18347 · Cited by 484
Mannose Receptor-Mediated Regulation of Serum Glycoprotein Homeostasis
Lee, S. J., Evers, S., Roeder, D., Parlow, A. F., Risteli, J., Risteli, L., Lee, Y. C., Feizi, T., Langen, H., & Nussenzweig, M. C. (2002) · Science · doi:10.1126/science.1069540 · Cited by 484
Heterogeneity of Monoclonal Antibodies
Liu, H., Gaza-Bulseco, G., Faldu, D., Chumsae, C., & Sun, J. (2008) · Journal of Pharmaceutical Sciences · doi:10.1002/jps.21180 · Cited by 481
Goetze, A. M., Liu, Y. D., Zhang, Z., Shah, B., Lee, E., Bondarenko, P. V., & Flynn, G. C. (2011) · Glycobiology · doi:10.1093/glycob/cwr027 · Cited by 467
Global metabolic inhibitors of sialyl- and fucosyltransferases remodel the glycome
Rillahan, C. D., Antonopoulos, A., Lefort, C. T., Sonon, R., Azadi, P., Ley, K., Dell, A., Haslam, S. M., & Paulson, J. C. (2012) · Nature Chemical Biology · doi:10.1038/nchembio.999 · Cited by 447
Glycan optimization of a human monoclonal antibody in the aquatic plant Lemna minor
Cox, K. M., Sterling, J. D., Regan, J. T., Gasdaska, J. R., Frantz, K. K., Peele, C. G., Black, A., Passmore, D., Moldovan-Loomis, C., Srinivasan, M., et al. (2006) · Nature Biotechnology · doi:10.1038/nbt1260 · Cited by 421
The Complete Nucleotide Sequence of the Human Immunoglobulin Heavy Chain Variable Region Locus
Matsuda, F., Ishii, K., Bourvagnet, P., Kuma, K.-I., Hayashida, H., Miyata, T., & Honjo, T. (1998) · The Journal of Experimental Medicine · doi:10.1084/jem.188.11.2151 · Cited by 401
Post-translational Modifications Differentially Affect IgG1 Conformation and Receptor Binding
Houde, D., Peng, Y., Berkowitz, S. A., & Engen, J. R. (2010) · Molecular & Cellular Proteomics · doi:10.1074/mcp.m900540-mcp200 · Cited by 393
Kanda, Y., Yamada, T., Mori, K., Okazaki, A., Inoue, M., Kitajima-Miyama, K., Kuni-Kamochi, R., Nakano, R., Yano, K., Kakita, S., et al. (2007) · Glycobiology · doi:10.1093/glycob/cwl057 · Cited by 372
The mannose receptor: linking homeostasis and immunity through sugar recognition
TAYLOR, P., GORDON, S., & MARTINEZPOMARES, L. (2005) · Trends in Immunology · doi:10.1016/j.it.2004.12.001 · Cited by 368
Marketed therapeutic antibodies compendium
Reichert, J. M. (2012) · mAbs · doi:10.4161/mabs.19931 · Cited by 368
The impact of glycosylation on monoclonal antibody conformation and stability
Zheng, K., Bantog, C., & Bayer, R. (2011) · mAbs · doi:10.4161/mabs.3.6.17922 · Cited by 342
Mimura, Y., Church, S., Ghirlando, R., Ashton, P. R., Dong, S., Goodall, M., Lund, J., & Jefferis, R. (2000) · Molecular Immunology · doi:10.1016/s0161-5890(00)00105-x · Cited by 329
Ferrara, C., Brünker, P., Suter, T., Moser, S., Püntener, U., & Umaña, P. (2006) · Biotechnology and Bioengineering · doi:10.1002/bit.20777 · Cited by 305
Structural and Functional Characterization of Disulfide Isoforms of the Human IgG2 Subclass
Dillon, T. M., Ricci, M. S., Vezina, C., Flynn, G. C., Liu, Y. D., Rehder, D. S., Plant, M., Henkle, B., Li, Y., Deechongkit, S., et al. (2008) · Journal of Biological Chemistry · doi:10.1074/jbc.m709988200 · Cited by 291
Human IgG2 Antibodies Display Disulfide-mediated Structural Isoforms
Wypych, J., Li, M., Guo, A., Zhang, Z., Martinez, T., Allen, M. J., Fodor, S., Kelner, D. N., Flynn, G. C., Liu, Y. D., et al. (2008) · Journal of Biological Chemistry · doi:10.1074/jbc.m709987200 · Cited by 286
In Vivo Deamidation Characterization of Monoclonal Antibody by LC/MS/MS
Huang, L., Lu, J., Wroblewski, V. J., Beals, J. M., & Riggin, R. M. (2005) · Analytical Chemistry · doi:10.1021/ac0494174 · Cited by 266
Isoaspartate in peptides and proteins: formation, significance, and analysis
Aswad, D. W., Paranandi, M. V., & Schurter, B. T. (2000) · Journal of Pharmaceutical and Biomedical Analysis · doi:10.1016/s0731-7085(99)00230-7 · Cited by 266
Chelius, D., Rehder, D. S., & Bondarenko, P. V. (2005) · Analytical Chemistry · doi:10.1021/ac050672d · Cited by 263
Anumula, K. R., & Dhume, S. T. (1998) · Glycobiology · doi:10.1093/glycob/8.7.685 · Cited by 262
Impact of methionine oxidation in human IgG1 Fc on serum half-life of monoclonal antibodies
Wang, W., Vlasak, J., Li, Y., Pristatsky, P., Fang, Y., Pittman, T., Roman, J., Wang, Y., Prueksaritanont, T., & Ionescu, R. (2011) · Molecular Immunology · doi:10.1016/j.molimm.2010.12.009 · Cited by 257
Beck, A., Wagner-Rousset, E., Bussat, M.-C., Lokteff, M., Klinguer-Hamour, C., Haeuw, J.-F., Goetsch, L., Wurch, T., Dorsselaer, A., & Corvaia, N. (2008) · Current Pharmaceutical Biotechnology · doi:10.2174/138920108786786411 · Cited by 246
Role of Oligosaccharide Residues of IgG1-Fc in FcγRIIb Binding
Mimura, Y., Sondermann, P., Ghirlando, R., Lund, J., Young, S. P., Goodall, M., & Jefferis, R. (2001) · Journal of Biological Chemistry · doi:10.1074/jbc.m107478200 · Cited by 236
Pharmacological significance of glycosylation in therapeutic proteins
Li, H., & d’Anjou, M. (2009) · Current Opinion in Biotechnology · doi:10.1016/j.copbio.2009.10.009 · Cited by 231
Ruhaak, L. R., Huhn, C., Waterreus, W.-J., de Boer, A. R., Neusüss, C., Hokke, C. H., Deelder, A. M., & Wuhrer, M. (2008) · Analytical Chemistry · doi:10.1021/ac800630x · Cited by 208
Yu, M., Brown, D., Reed, C., Chung, S., Lutman, J., Stefanich, E., Wong, A., Stephan, J.-P., & Bayer, R. (2012) · mAbs · doi:10.4161/mabs.20737 · Cited by 203
NMR analysis demonstrates immunoglobulin G N-glycans are accessible and dynamic
Barb, A. W., & Prestegard, J. H. (2011) · Nature Chemical Biology · doi:10.1038/nchembio.511 · Cited by 186
N-terminal Glutamate to Pyroglutamate Conversion in Vivo for Human IgG2 Antibodies
Liu, Y. D., Goetze, A. M., Bass, R. B., & Flynn, G. C. (2011) · Journal of Biological Chemistry · doi:10.1074/jbc.m110.185041 · Cited by 175
Non-fucosylated therapeutic antibodies as next-generation therapeutic antibodies
Satoh, M., Iida, S., & Shitara, K. (2006) · Expert Opinion on Biological Therapy · doi:10.1517/14712598.6.11.1161 · Cited by 175
Zou, G., Ochiai, H., Huang, W., Yang, Q., Li, C., & Wang, L.-X. (2011) · Journal of the American Chemical Society · doi:10.1021/ja208390n · Cited by 166
Allavena, P., Chieppa, M., Monti, P., & Piemonti, L. (2004) · Critical Reviews in Immunology · doi:10.1615/critrevimmunol.v24.i3.20 · Cited by 161
Melmer, M., Stangler, T., Premstaller, A., & Lindner, W. (2011) · Journal of Chromatography A · doi:10.1016/j.chroma.2010.10.122 · Cited by 159
Impact of variable domain glycosylation on antibody clearance: An LC/MS characterization
Huang, L., Biolsi, S., Bales, K. R., & Kuchibhotla, U. (2005) · Analytical Biochemistry · doi:10.1016/j.ab.2005.11.012 · Cited by 144
Impact of Glycosylation on Effector Functions of Therapeutic IgG
Abès, R., & Teillaud, J. (2010) · Pharmaceuticals · doi:10.3390/ph3010146 · Cited by 137
Jones, A. J. S., Papac, D. I., Chin, E. H., Keck, R. G., Baughman, S. A., Lin, Y. S., Kneer, J., & Battersby, J. E. (2007) · Glycobiology · doi:10.1093/glycob/cwm017 · Cited by 137
Gennaro, L. A., & Salas‐Solano, O. (2008) · Analytical Chemistry · doi:10.1021/ac800152h · Cited by 136
Recognition of immunoglobulins by Fcγ receptors
Radaev, S., & Sun, P. D. (2002) · Molecular Immunology · doi:10.1016/s0161-5890(02)00036-6 · Cited by 136
Ito, A., Ishida, T., Yano, H., Inagaki, A., Suzuki, S., Sato, F., Takino, H., Mori, F., Ri, M., Kusumoto, S., et al. (2008) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-008-0632-0 · Cited by 133
Chen, X., & Flynn, G. C. (2007) · Analytical Biochemistry · doi:10.1016/j.ab.2007.08.012 · Cited by 127
Naturally occurring glycan forms of human immunoglobulins G1 and G2
Flynn, G. C., Chen, X., Liu, D., Shah, B., & Zhang, Z. (2010) · Molecular Immunology · doi:10.1016/j.molimm.2010.04.006 · Cited by 126
Kanda, Y., Imai, H., Kuni‐Kamochi, R., Mori, K., Inoue, M., Kitajima-Miyama, K., Okazaki, A., Iida, S., Shitara, K., & Satoh, M. (2007) · Journal of Biotechnology · doi:10.1016/j.jbiotec.2007.04.025 · Cited by 125
Gerdes, C. A., Nicolini, V., Herter, S., van Puijenbroek, E., Lang, S., Roemmele, M., Moessner, E., Freytag, O., Friess, T., Ries, C. H., et al. (2012) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-12-0989 · Cited by 124
Increased serum clearance of oligomannose species present on a human IgG1 molecule
Alessandri, L., Ouellette, D., Acquah, A., Rieser, M., LeBlond, D. J., Saltarelli, M. J., Radziejewski, C. H., Fujimori, T., & Correia, I. (2012) · mAbs · doi:10.4161/mabs.20450 · Cited by 120
The effect of Fc glycan forms on human IgG2 antibody clearance in humans
Chen, X., Liu, D., & Flynn, G. C. (2008) · Glycobiology · doi:10.1093/glycob/cwn120 · Cited by 115
HILIC analysis of fluorescence-labeled N-glycans from recombinant biopharmaceuticals
Melmer, M., Stangler, T., Schiefermeier, M., Brunner, W., Toll, H., Rupprechter, A., Lindner, W., & Premstaller, A. (2010) · Analytical and Bioanalytical Chemistry · doi:10.1007/s00216-010-3988-x · Cited by 104
Millward, T. A., Heitzmann, M., Bill, K., Längle, U., Schumacher, P., & Forrer, K. (2007) · Biologicals · doi:10.1016/j.biologicals.2007.05.003 · Cited by 91
Critical Comparison of MS and Immunoassays for the Bioanalysis of Therapeutic Antibodies
Ezan, É., & Bitsch, F. (2009) · Bioanalysis · doi:10.4155/bio.09.121 · Cited by 90
C‐terminal lysine processing of human immunoglobulin G2 heavy chain in vivo
Cai, B., Pan, H., & Flynn, G. (2011) · Biotechnology and Bioengineering · doi:10.1002/bit.22933 · Cited by 89
Rates and impact of human antibody glycation in vivo
Goetze, A. M., Liu, D., Arroll, T., Chu, L., & Flynn, G. C. (2011) · Glycobiology · doi:10.1093/glycob/cwr141 · Cited by 88
Haselberg, R., Brinks, V., Hawe, A., de Jong, G. J., & Somsen, G. W. (2011) · Analytical and Bioanalytical Chemistry · doi:10.1007/s00216-011-4738-4 · Cited by 83
GlycoFi's technology to control the glycosylation of recombinant therapeutic proteins
Beck, A., Cochet, O., & Wurch, T. (2009) · Expert Opinion on Drug Discovery · doi:10.1517/17460440903413504 · Cited by 80
Gennaro, L. A., Delaney, J., Vouros, P., Harvey, D. J., & Domon, B. (2002) · Rapid Communications in Mass Spectrometry · doi:10.1002/rcm.564 · Cited by 77
Liu, L., Stadheim, A., Hamuro, L., Pittman, T. J., Wang, W., Zha, D., Hochman, J. H., & Prueksaritanont, T. (2011) · Biologicals · doi:10.1016/j.biologicals.2011.06.002 · Cited by 76
Keck, R. G., Nayak, N., Lerner, L. E., Raju, S., Ma, S., Schreitmueller, T., Chamow, S., Moorhouse, K., Kotts, C. E., & Jones, A. J. S. (2007) · Biologicals · doi:10.1016/j.biologicals.2007.05.004 · Cited by 72
Liu, L., Gomathinayagam, S., Hamuro, L., Prueksaritanont, T., Wang, W., Stadheim, T. A., & Hamilton, S. R. (2012) · Pharmaceutical Research · doi:10.1007/s11095-012-0921-3 · Cited by 67
Prater, B. D., Connelly, H. M., Qin, Q., & Cockrill, S. L. (2008) · Analytical Biochemistry · doi:10.1016/j.ab.2008.10.023 · Cited by 66
Reversed-phase liquid-chromatographic mass spectrometric N-glycan analysis of biopharmaceuticals
Higel, F., Demelbauer, U. M., Seidl, A., Frieß, W., & Sörgel, F. (2013) · Analytical and Bioanalytical Chemistry · doi:10.1007/s00216-012-6690-3 · Cited by 64
Self-citationKogelberg, H., Tolner, B., Sharma, S. K., Lowdell, M. W., Qureshi, U., Robson, M. P., Hillyer, T., Pedley, R. B., Vervecken, W., Contreras, R., et al. (2006) · Glycobiology · doi:10.1093/glycob/cwl053 · Cited by 64
Nakano, M., Higo, D., Arai, E., Nakagawa, T., Kakehi, K., Taniguchi, N., & Kondo, A. (2008) · Glycobiology · doi:10.1093/glycob/cwn115 · Cited by 63
Differential clearance of glycoforms of IgG in normal and autoimmune-prone mice
Newkirk, M. M., Novick, J., Stevenson, M. M., Fournier, M.-J., & Apostolakos, P. (1996) · Clinical & Experimental Immunology · doi:10.1046/j.1365-2249.1996.d01-847.x · Cited by 62
Electrophoretic evidence for the presence of structural isoforms specific for the IgG2 isotype
Guo, A., Han, M., Martinez, T., Ketchem, R. R., Novick, S., Jochheim, C. M., & Balland, A. (2008) · Electrophoresis · doi:10.1002/elps.200800083 · Cited by 56
Bongers, J., Devincentis, J., Fu, J., Huang, P., Kirkley, D. H., Leister, K. J., Liu, P., Ludwig, R. T., Rumney, K., Tao, L., et al. (2011) · Journal of Chromatography A · doi:10.1016/j.chroma.2011.08.089 · Cited by 53
Real‐time product attribute control to manufacture antibodies with defined N‐linked glycan levels
Zupke, C., Brady, L. J., Slade, P. G., Clark, P. C. T., Caspary, R. G., Livingston, B., Taylor, L. D., Bigham, K., Morris, A. E., & Bailey, R. W. (2015) · Biotechnology Progress · doi:10.1002/btpr.2136 · Cited by 43
Glutamine deamidation of a recombinant monoclonal antibody
Liu, H., Gaza‐Bulseco, G., & Chumsae, C. M. (2008) · Rapid Communications in Mass Spectrometry · doi:10.1002/rcm.3831 · Cited by 43
Nanoscale reversed-phase liquid chromatography–mass spectrometry of permethylated N-glycans
Ritamo, I., Räbinä, J., Natunen, S., & Valmu, L. (2013) · Analytical and Bioanalytical Chemistry · doi:10.1007/s00216-012-6680-5 · Cited by 28
Impact of Glycation on Antibody Clearance
Yang, J., Primack, R., Frohn, M., Wang, W., Luan, P., Retter, M. W., & Flynn, G. C. (2014) · The AAPS Journal · doi:10.1208/s12248-014-9694-4 · Cited by 18
Higel, F., Seidl, A., Demelbauer, U. M., Viertlboeck-Schudy, M., Koppenburg, V., Kronthaler, U. O., Sörgel, F., & Frieß, W. (2015) · Pharmaceutical Research · doi:10.1007/s11095-015-1724-0 · Cited by 15
Self-citationHigel, F., Seidl, A., Demelbauer, U. M., Sörgel, F., & Frieß, W. (2014) · mAbs · doi:10.4161/mabs.29263 · Cited by 10
Self-citation
Cited by
Pharmacokinetics of Monoclonal Antibodies
Ryman, J. T., & Meibohm, B. (2017) · CPT: Pharmacometrics & Systems Pharmacology · doi:10.1002/psp4.12224 · Cited by 802
Nanoparticle-Based Immunochemical Biosensors and Assays: Recent Advances and Challenges
Farka, Z., Juřík, T., Kovář, D., Trnková, L., & Skládal, P. (2017) · Chemical Reviews · doi:10.1021/acs.chemrev.7b00037 · Cited by 694
The Increasingly Human and Profitable Monoclonal Antibody Market
Grilo, A. L., & Mantalaris, A. (2019) · Trends in Biotechnology · doi:10.1016/j.tibtech.2018.05.014 · Cited by 462
Graf, T., Heinrich, K., Grunert, I., Wegele, H., Haberger, M., Bulau, P., & Leiss, M. (2020) · Journal of Pharmaceutical and Biomedical Analysis · doi:10.1016/j.jpba.2020.113251 · Cited by 46
mAb Production Modeling and Design Space Evaluation Including Glycosylation Process
Yang, O., & Ierapetritou, M. (2021) · Processes · doi:10.3390/pr9020324 · Cited by 26
Metadata
- Authors
- Higel, F., Seidl, A., Sörgel, F., & Friess, W.
- Venue
- European Journal of Pharmaceutics and Biopharmaceutics
- Publisher
- Elsevier BV
- Published
- 2016-03
- Volume
- 100
- Pages
- 94-100
- ISSN
- 0939-6411 (ISSN-L)
- OpenAlex
- W2239052723
- Cited by
- 360
- References
- 83
- FWCI
- 32.59
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.